HK1198370A1 - Nucleic acids specifically binding cgrp - Google Patents

Nucleic acids specifically binding cgrp Download PDF

Info

Publication number
HK1198370A1
HK1198370A1 HK14111873.3A HK14111873A HK1198370A1 HK 1198370 A1 HK1198370 A1 HK 1198370A1 HK 14111873 A HK14111873 A HK 14111873A HK 1198370 A1 HK1198370 A1 HK 1198370A1
Authority
HK
Hong Kong
Prior art keywords
nucleic acids
specifically binding
acids specifically
cgrp
binding cgrp
Prior art date
Application number
HK14111873.3A
Other languages
English (en)
Chinese (zh)
Inventor
Schülzchen Simone
Purschke Werner
Jarosch Florian
Höhlig Kai
Maasch Christian
Klussmann Sven
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/000089 external-priority patent/WO2012095303A1/en
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of HK1198370A1 publication Critical patent/HK1198370A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14111873.3A 2012-01-10 2013-01-10 Nucleic acids specifically binding cgrp HK1198370A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12000105 2012-01-10
EPPCT/EP2012/000089 2012-01-10
PCT/EP2012/000089 WO2012095303A1 (en) 2011-01-10 2012-01-10 Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
EP12000105.2 2012-01-10
PCT/EP2013/000055 WO2013104539A1 (en) 2012-01-10 2013-01-10 Nucleic acids specifically binding cgrp

Publications (1)

Publication Number Publication Date
HK1198370A1 true HK1198370A1 (en) 2015-04-10

Family

ID=48781062

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14111873.3A HK1198370A1 (en) 2012-01-10 2013-01-10 Nucleic acids specifically binding cgrp

Country Status (14)

Country Link
US (1) US9163243B2 (https=)
EP (1) EP2802659A1 (https=)
JP (1) JP2015506174A (https=)
KR (1) KR20140111704A (https=)
CN (1) CN104136612A (https=)
AU (1) AU2013209130A1 (https=)
BR (1) BR112014016939A2 (https=)
CA (1) CA2860809A1 (https=)
HK (1) HK1198370A1 (https=)
IL (1) IL233515A0 (https=)
MX (1) MX2014008456A (https=)
RU (1) RU2014132706A (https=)
SG (1) SG11201403769YA (https=)
WO (1) WO2013104539A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013104540A1 (en) 2012-01-10 2013-07-18 Noxxon Pharma Ag New c5a binding nucleic acids
PE20161439A1 (es) 2014-03-21 2017-01-26 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
JP6584868B2 (ja) * 2015-02-25 2019-10-02 学校法人 関西大学 ゲル素材及びその製造方法
EA201890578A1 (ru) * 2015-09-24 2018-12-28 Тева Фармасьютикалз Интернэшнл Гмбх Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
ES2607639B1 (es) 2015-09-30 2018-02-28 Urquima, S.A Sal de ácido maleico de un intermedio de silodosina
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
KR102929968B1 (ko) * 2018-11-12 2026-02-25 아프타리온 바이오테크 아게 Cxcl8 결합 핵산

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
AU732820B2 (en) 1995-06-02 2001-05-03 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to growth factors
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
DE69433747D1 (de) 1994-08-16 2004-06-03 Human Genome Sciences Inc Calcitoninrezeptor
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
RU2180311C1 (ru) 2001-07-05 2002-03-10 Мешалкин Георгий Алексеевич Защитная пробка
US7629456B2 (en) 2001-10-26 2009-12-08 Noxxon Pharma Ag Modified L-nucleic acid
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
WO2003070823A2 (en) 2002-02-20 2003-08-28 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
US7879991B2 (en) * 2002-05-06 2011-02-01 Noxxon Pharma Ag CGRP binding nucleic acids
MXPA05011022A (es) 2003-04-13 2006-04-27 Enzon Pharmaceuticals Inc Profarmacos oligonucleotidos polimericos.
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US20090281296A1 (en) 2004-02-09 2009-11-12 Supramol Parenteral Colloid Gmbh Process for the production of conjugates from polysaccharides and polynucelotides
MXPA06010782A (es) 2004-03-23 2007-03-28 Complex Biosystems Gmbh Ligador de profarmaco.
CN101098703B (zh) 2004-11-05 2011-08-03 费城儿童医院 用于分子治疗的生物降解连接剂
EP1877069A2 (de) * 2005-05-04 2008-01-16 Noxxon Pharma AG Neue verwendung von spiegelmeren
JP2010503707A (ja) 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー
WO2008052774A2 (en) 2006-10-31 2008-05-08 Noxxon Pharma Ag Methods for detection of a single- or double-stranded nucleic acid molecule
US8871920B2 (en) 2010-04-21 2014-10-28 Noxxon Pharma Ag Lipid binding nucleic acids
AU2012206750A1 (en) * 2011-01-10 2013-07-18 Noxxon Pharma Ag Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same

Also Published As

Publication number Publication date
KR20140111704A (ko) 2014-09-19
US9163243B2 (en) 2015-10-20
MX2014008456A (es) 2014-11-25
IL233515A0 (en) 2014-08-31
RU2014132706A (ru) 2016-02-27
BR112014016939A2 (pt) 2019-09-24
AU2013209130A1 (en) 2014-07-10
CA2860809A1 (en) 2013-07-18
EP2802659A1 (en) 2014-11-19
JP2015506174A (ja) 2015-03-02
SG11201403769YA (en) 2014-07-30
US20150031755A1 (en) 2015-01-29
CN104136612A (zh) 2014-11-05
WO2013104539A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
HK1198370A1 (en) Nucleic acids specifically binding cgrp
Murray et al. Gene duplication, loss and selection in the evolution of saxitoxin biosynthesis in alveolates
EA201791417A1 (ru) Супрессия гена гентингтина, индуцированная рнк-интерференцией
IL250539B (en) Nucleotides modified for nucleic acid synthesis, a kit containing such nucleotides and their use for the production of synthetic nucleic acid sequences or genes
WO2015081229A3 (en) Selective amplification of nucleic acid sequences
SG11201809961TA (en) Variants of a dna polymerase of the polx family
WO2007145612A8 (en) Paired end sequencing
EP4520841A3 (en) Enzyme- and amplification-free sequencing
PH12019501302A1 (en) Use of biological rna scaffolds with in vitro selection to generate robust small molecule binding aptamers for genetically encodable biosensors
IN2012DN00403A (https=)
WO2008087641A3 (en) H19 silencing nucleic acid agents for treating rheumatoid arthritis
WO2014096992A8 (en) Acetyl transferases and their use for producing carotenoids
EP3368178A4 (en) METHOD AND SYSTEMS FOR CONTROLLING THROUGH DNA, RNA AND OTHER BIOLOGICAL MOLECULES THAT GO THROUGH NANOPORES
WO2007005645A3 (en) Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
JP2016528918A5 (https=)
BRPI0815392A2 (pt) Método para produzir planta transgênica, planta transgênica, uso de uma sequência de ácido nucleico exógeno, gene quimérico, vetor de transformação de planta, e , planta ou célula de planta.
WO2012103442A3 (en) Paired end bead amplification and high throughput sequencing
WO2013091612A3 (de) Neue aus pflanzen stammende cis-regulatorische elemente für die entwicklung pathogen-responsiver chimärer promotoren
WO2016106387A3 (en) Nucleic acid aptamers to treat histone-induced disease states
Varshney et al. Identification of an RNA aptamer binding hTERT-derived peptide and inhibiting telomerase activity in MCF7 cells
WO2015150482A8 (en) A combination product comprising a nucleic acid structure and a single-stranded nucleic acid molecule
PH12017500698A1 (en) Synthetic bi-directional plant promoter
DK1891220T3 (da) Autoaktiveret resistensprotein
JP2016108250A5 (https=)
Wu et al. Single aromatic residue location alters nucleic acid binding and chaperone function of FIV nucleocapsid protein